Provided by Tiger Fintech (Singapore) Pte. Ltd.

KALA BIO

3.30
+0.18005.77%
Post-market: 3.400.1000+3.03%19:23 EDT
Volume:89.62K
Turnover:297.19K
Market Cap:21.29M
PE:-0.33
High:3.56
Open:3.20
Low:3.20
Close:3.12
Loading ...

Company Profile

Company Name:
KALA BIO
Exchange:
NASDAQ
Establishment Date:
2009
Employees:
38
Office Location:
1167 Massachusetts Avenue,Arlington,Massachusetts,United States
Zip Code:
02476
Fax:
781 642 0399
Introduction:
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.

Directors

Name
Position
Mark Iwicki
Chief Executive Officer and Chairman of the Board
Andrew I. Koven
Director,Lead Independent Director
C. Daniel Myers
Director
Gregory D. Perry
Director
Howard Rosen
Director
Marjan Farid
Director
Mark S. Blumenkranz
Director
Robert Paull
Director

Shareholders

Name
Position
Mark Iwicki
Chief Executive Officer and Chairman of the Board
Todd Bazemore
President and Chief Operating Officer
Mary Reumuth
Chief Financial Officer and Treasurer
Darius Kharabi
Chief Business Officer
Eric L. Trachtenberg
General Counsel, Chief Compliance Officer and Corporate Secretary
Kim Brazzell
Head of Research and Development and Chief Medical Officer